% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Merz:141402,
      author       = {M. Merz and A. Jauch and T. Hielscher$^*$ and T. Bochtler
                      and S. O. Schönland and A. Seckinger and D. Hose and U.
                      Bertsch and K. Neben and M. S. Raab$^*$ and J. Hillengass
                      and H. Salwender and I. W. Blau and H.-W. Lindemann and I.
                      G. H. Schmidt-Wolf and C. Scheid and M. Haenel and K. C.
                      Weisel and H. Goldschmidt},
      title        = {{P}rognostic significance of cytogenetic heterogeneity in
                      patients with newly diagnosed multiple myeloma.},
      journal      = {Blood advances},
      volume       = {2},
      number       = {1},
      issn         = {2473-9537},
      address      = {Washington, DC},
      publisher    = {American Society of Hematology},
      reportid     = {DKFZ-2018-01908},
      pages        = {1 - 9},
      year         = {2018},
      abstract     = {We investigated subclonal cytogenetic aberrations (CA)
                      detected by interphase fluorescence in situ hybridization
                      (iFISH) in patients with newly diagnosed multiple myeloma
                      (MM) enrolled in the Haemato Oncology Foundation for Adults
                      in the Netherlands (HOVON)-65/German-Speaking MM Group
                      (GMMG)-HD4 phase 3 trial. Patients were either treated with
                      3 cycles of vincristine, Adriamycin, and dexamethasone or
                      bortezomib, Adriamycin, and dexamethasone and then
                      thalidomide or bortezomib maintenance after tandem
                      autologous transplantation. Subclones were defined either by
                      presence of different copy numbers of the same chromosome
                      loci and/or CA present in at least $30\%$ less and maximally
                      2/3 of cells compared with the main clone CA. Patients with
                      subclones harbored more frequently high risk $(31.0\%)$ or
                      hyperdiploid main clone aberrations $(24.8\%)$ than patients
                      with t(11;14) in the main clone $(10.1\%).$ Gains and
                      deletions of c-MYC were the only CA that occurred more
                      frequently as subclone $(8.1\%/20.5\%)$ than main clone
                      $(6.2\%/3.9\%,$ respectively). Treatment with bortezomib
                      completely overcame the negative prognosis of high-risk CA
                      in patients without subclones, but not in patients with
                      additional subclonal CA. High-risk patients treated without
                      bortezomib showed dismal outcome whether subclones were
                      present or not. Cytogenetic heterogeneity defined by
                      subclonal CA is of major prognostic significance in newly
                      diagnosed MM patients treated with bortezomib within the
                      HOVON-65/GMMG-HD4 trial.},
      cin          = {C060 / G170},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)G170-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29344579},
      pmc          = {pmc:PMC5761630},
      doi          = {10.1182/bloodadvances.2017013334},
      url          = {https://inrepo02.dkfz.de/record/141402},
}